Breaking Finance News

Zacks Investment Research upgraded Heron Therapeutics Inc (NASDAQ:HRTX) to Hold in a report released today.

Yesterday Heron Therapeutics Inc (NASDAQ:HRTX) traded -5.29% lower at $16.31. The company’s 50-day moving average is $18.38 and its 200-day moving average is $18.91. The last stock close price is down -13.85% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 578,634 shares of the stock were exchanged, down from an avg. volume of 735,735

Zacks Investment Research has upgraded Heron Therapeutics Inc (NASDAQ:HRTX) to Hold in a report released on 10/11/2016.

Performance Chart

Heron Therapeutics Inc (NASDAQ:HRTX)

With a total market value of $0, Heron Therapeutics Inc has with a one year low of $15.13 and a one year high of $31.32 .

A total of 9 analysts have released a research note on HRTX. Four analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $46.11.

More About Heron Therapeutics Inc (NASDAQ:HRTX)

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *